JP2007526238A - マクロファージまたは葉酸受容体を標的とする狼瘡治療法 - Google Patents
マクロファージまたは葉酸受容体を標的とする狼瘡治療法 Download PDFInfo
- Publication number
- JP2007526238A JP2007526238A JP2006532814A JP2006532814A JP2007526238A JP 2007526238 A JP2007526238 A JP 2007526238A JP 2006532814 A JP2006532814 A JP 2006532814A JP 2006532814 A JP2006532814 A JP 2006532814A JP 2007526238 A JP2007526238 A JP 2007526238A
- Authority
- JP
- Japan
- Prior art keywords
- lupus erythematosus
- group
- ligand
- conjugate
- macrophages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
【選択図】図3
Description
本出願は、2003年5月6日出願の米国仮出願第60/468,330号の利益を主張する。
本発明はエリテマトーデス(紅斑性狼瘡)の治療法に関する。より詳細には、活性化されたマクロファージ、またはその他の刺激された免疫細胞に結合するリガンドが、免疫原物質、細胞毒素、または、別の薬剤であって、マクロファージ機能、または、その他の刺激された免疫細胞の機能を改変する薬剤と結合され、エリテマトーデス治療のために患者に投与される。
[エリテマトーデス感受性MRL/MpJ-Tnfrsf6lprマウスの器官におけるEC20取り込みの分析]
葉酸塩標的99mTcキレート化学成分(EC20、国際公開第WO 03/092742号参照、引用により本明細書に含む)の結合が、エリテマトーデスに罹り易いマウスの器官に検出されるかどうかを確定するために、エリテマトーデス感受性MRL/MpJ-Tnfrsf6lprマウスを用いた。エリテマトーデス感受性MRL/MpJ-Tnfrsf6lprマウスは、Tnfrsfタンパク(腫瘍壊死因子ファミリーの一員である)をコードする遺伝子内部に突然変異を持ち、3月齢で、免疫複合体の循環レベルに著明な増大と、重篤な糸球体腎炎を呈する。雌のMRL/MpJ-Tnfrsf6lprマウスは17週の寿命を持つ。MRL/MpJマウスと表示される対照グループのマウスでは、3月齢では軽度の糸球体病巣しか見られず、雌は73週の寿命を持つ。
[エリテマトーデス感受性MRL/MpJ-Tnfrsf6lprマウスの生存率に及ぼす葉酸-FITC結合体の効果]
雌の、エリテマトーデス感受性MRL/MpJ-Tnfrsf6lprマウスをジャクソン・ラボラトリーズ(バーハーバー、メイン州)から購入した。5週齢のマウス(グループ当たりn=9)を、0日目に、TiterMax Gold(登録商標)アジュバント(葉酸−FITC結合体と1:1容量/容量比)を、フルオレセインイソチオシアネート(FITC)−KLH結合体と組み合わせて、複数箇所に(2箇所にそれぞれ50 μl容量で)(1匹のマウス当たり合計50 μg)皮下投与して免疫化した。有効であれば、従来技術で既知の、任意のアジュバントを使用することが可能である。20日目に、マウスを葉酸欠損食餌で養った。28日目(9週齢時)に、前述のようにして、マウスを再度TiterMax Gold(登録商標)とフルオレセインイソチオシアネート(FITC)-KLH結合体で免疫化した。
Claims (8)
- エリテマトーデス(紅斑性狼瘡)治療用薬剤の製造における、一般式
L−X
の結合体の用法であって、
式中、基Lは、活性化マクロファージに結合することが可能なリガンドを含み、かつ、基Xは、免疫原物質、細胞毒素、または、マクロファージ機能を改変することが可能な他の化合物を含むことを特徴とする前記用法。 - 前記基Lは、ビタミン、または、そのビタミン受容体結合性類縁体または誘導体を含むことを特徴とする、請求項1の用法。
- Lは、葉酸受容体結合性リガンドを含むことを特徴とする、請求項1または2の用法。
- Lは、抗体、または活性化マクロファージ結合性抗体断片を含むことを特徴とする、請求項1の用法。
- 前記基Xは免疫原物質を含むことを特徴とする、請求項1、2、または3の用法。
- 前記基Xは細胞毒素を含むことを特徴とする、請求項1、2、または3の用法。
- 前記基Xはさらにリポソームを含むことを特徴とする、請求項6の用法。
- 前記基Xはサイトカインを含むことを特徴とする、請求項2の用法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46833003P | 2003-05-06 | 2003-05-06 | |
PCT/US2004/014097 WO2004100983A2 (en) | 2003-05-06 | 2004-05-06 | Treatment of lupus targeting the macrophages or the folate receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007526238A true JP2007526238A (ja) | 2007-09-13 |
JP2007526238A5 JP2007526238A5 (ja) | 2009-01-08 |
Family
ID=33452201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006532814A Pending JP2007526238A (ja) | 2003-05-06 | 2004-05-06 | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060204565A1 (ja) |
EP (1) | EP1622646B1 (ja) |
JP (1) | JP2007526238A (ja) |
CA (1) | CA2524441C (ja) |
WO (1) | WO2004100983A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040015234A (ko) * | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
DK2260875T3 (da) | 2002-05-06 | 2014-06-30 | Endocyte Inc | Folatreceptor-targetede billeddannelsesmidler |
ATE412897T1 (de) * | 2003-05-30 | 2008-11-15 | Purdue Research Foundation | Diagnoseverfahren für atherosklerose |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CA2592302C (en) * | 2004-12-23 | 2013-10-29 | Purdue Research Foundation | Positron emission tomography imaging method |
JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
WO2007038346A2 (en) | 2005-09-23 | 2007-04-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
WO2008093166A2 (en) * | 2006-05-11 | 2008-08-07 | Ghent University | Sialoadhesin-related compositions and methods |
WO2008127298A2 (en) * | 2006-10-24 | 2008-10-23 | Subroto Chatterjee | Staphylococcal enterotoxin b peptide compositions and methods of use |
EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
EP2109466B1 (en) | 2007-02-07 | 2014-11-12 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
WO2008148001A2 (en) * | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
US20130071321A1 (en) | 2010-05-28 | 2013-03-21 | Purdue Research Foundation | Delivery of agents to inflamed tissues using folate-targeted liposomes |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
ES2811347T3 (es) | 2015-08-14 | 2021-03-11 | Endocyte Inc | Método de formación de imágenes con un compuesto quelante |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002503676A (ja) * | 1998-02-17 | 2002-02-05 | メダレツクス・インコーポレーテツド | Fcレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断 |
WO2002087424A2 (en) * | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
WO2003028634A2 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US5266333A (en) * | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
ATE211394T1 (de) * | 1997-06-20 | 2002-01-15 | Tanox Pharma B V | Anti-cd40l immunotoxine zur behandlung von krankheiten |
CZ304942B6 (cs) * | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
CA2469263A1 (en) * | 2001-12-21 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Raf/ras binding compounds |
DK2260875T3 (da) * | 2002-05-06 | 2014-06-30 | Endocyte Inc | Folatreceptor-targetede billeddannelsesmidler |
-
2004
- 2004-05-06 JP JP2006532814A patent/JP2007526238A/ja active Pending
- 2004-05-06 CA CA2524441A patent/CA2524441C/en not_active Expired - Fee Related
- 2004-05-06 EP EP04751467A patent/EP1622646B1/en not_active Expired - Lifetime
- 2004-05-06 WO PCT/US2004/014097 patent/WO2004100983A2/en active Search and Examination
- 2004-05-06 US US10/552,569 patent/US20060204565A1/en not_active Abandoned
-
2007
- 2007-11-30 US US11/948,656 patent/US20080119475A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002503676A (ja) * | 1998-02-17 | 2002-02-05 | メダレツクス・インコーポレーテツド | Fcレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断 |
WO2002087424A2 (en) * | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
WO2003028634A2 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
Also Published As
Publication number | Publication date |
---|---|
EP1622646A2 (en) | 2006-02-08 |
WO2004100983A3 (en) | 2005-11-10 |
US20080119475A1 (en) | 2008-05-22 |
US20060204565A1 (en) | 2006-09-14 |
CA2524441C (en) | 2012-03-20 |
EP1622646B1 (en) | 2012-08-08 |
WO2004100983A2 (en) | 2004-11-25 |
CA2524441A1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080119475A1 (en) | Conjugates And Use Thereof | |
JP5175723B2 (ja) | 単球介在性疾患を治療するための組成物の調製 | |
US7033594B2 (en) | Method of treatment using ligand-immunogen conjugates | |
US7740854B2 (en) | Treatment of macrophage mediated disease | |
AU2001256970A1 (en) | Method of treatment using ligand-immunogen conjugates | |
US20090012009A1 (en) | Composition and Method for Treating Inflammatory Disease | |
JP5554713B2 (ja) | 接合体を投与する方法 | |
US8168164B2 (en) | Targeted conjugates and radiation | |
AU2007229371C1 (en) | Treatment and diagnosis of macrophage mediated disease | |
ZA200207768B (en) | Method of treatment using ligand-immunogen conjugates. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100430 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100512 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100531 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100701 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100802 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100824 |